Biotech | August 12, 2021
Global cell expansion market poised for huge growth
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The aim is to create new genomics solutions that could combat cancer and advance market access
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Advances deployment of mRNA technology across vaccines and therapeutics development
Startup receives US $ 5 million in first round of funding
Apollo hospital-Hyderabad, Kainos Hospital-Rohtak and Apex Hospital Jaipur have deployed this solution
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The Cephalosporin Injectables plant has a total capacity of 26.4 million vials per year while Ethiopia is having a demand for 16 million vials
In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
